Cargando…

Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial

BACKGROUND: Fluticasone furoate (FF) is a novel long-acting inhaled corticosteroid (ICS). This double-blind, placebo-controlled randomized study evaluated the efficacy and safety of FF 200 mcg or 400 mcg once daily, either in the morning or in the evening, and FF 200 mcg twice daily (morning and eve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Woodcock, Ashley, Bateman, Eric D, Busse, William W, Lötvall, Jan, Snowise, Neil G, Forth, Richard, Jacques, Loretta, Haumann, Brett, Bleecker, Eugene R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217852/ https://www.ncbi.nlm.nih.gov/pubmed/21977941 http://dx.doi.org/10.1186/1465-9921-12-132

Ejemplares similares

Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma
por: Woodcock, Ashley, et al.
Publicado: (2011)

Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma
por: O’Byrne, Paul M., et al.
Publicado: (2014)

Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial
por: O’Byrne, Paul M, et al.
Publicado: (2014)

Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone
por: Bateman, Eric D, et al.
Publicado: (2014)

Once-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial
por: Busse, W W, et al.
Publicado: (2014)

Efficacy and Safety of Fluticasone Furoate/Vilanterol Compared With Fluticasone Propionate/Salmeterol Combination in Adult and Adolescent Patients With Persistent Asthma: A Randomized Trial
por: Woodcock, Ashley, et al.
Publicado: (2013)

Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study
por: Woodcock, Ashley, et al.
Publicado: (2014)

Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β(2) agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial
por: Busse, William W, et al.
Publicado: (2013)

Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma
por: O’Byrne, Paul M., et al.
Publicado: (2016)

Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial
por: Lötvall, J, et al.
Publicado: (2012)

Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design
por: Worsley, Sally, et al.
Publicado: (2019)

Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy
por: Albertson, Timothy E, et al.
Publicado: (2016)

Patients with Asthma Prescribed Once-Daily Fluticasone Furoate/Vilanterol or Twice-Daily Fluticasone Propionate/Salmeterol as Maintenance Treatment: Analysis from a Claims Database
por: Atsuta, Ryo, et al.
Publicado: (2018)

Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma–mixed treatment comparisons of clinical efficacy
por: Svedsater, Henrik, et al.
Publicado: (2016)

Comparison of vilanterol, a novel long-acting beta(2) agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids
por: Lötvall, Jan, et al.
Publicado: (2014)

A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD
por: Bhatt, Surya P, et al.
Publicado: (2017)

A randomized, double-blind, placebo-controlled, parallel-group study of once-daily inhaled fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis of children with asthma
por: Bareille, Philippe, et al.
Publicado: (2020)

Comparative Meta-Analysis of the Efficacy of Once-Daily Fluticasone Furoate 100 µG Versus Twice-Daily Fluticasone Propionate 250 µG in Adolescents and Adults with Persistent Asthma
por: Tomlinson, Ryan, et al.
Publicado: (2017)

Efficacy and Safety of Once Daily Fluticasone Furoate Nasal Spray for Treatment of Irritant (Non-allergic) Rhinitis
por: Tantilipikorn, Pongsakorn, et al.
Publicado: (2010)

Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial
por: Furuhashi, Kazuki, et al.
Publicado: (2019)

Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination
por: Oliver, A, et al.
Publicado: (2013)

149 Once Daily Intranasal Fluticasone Furoate Decreases Daytime Sleepiness and Improves Cognitive Performance in Symptomatic Seasonal Allergic Rhinitis
por: Diaz, Alejandro
Publicado: (2012)

Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study
por: Allen, Ann, et al.
Publicado: (2013)

Efficacy of mometasone furoate and fluticasone furoate on persistent allergic rhinoconjunctivitis
por: Aneeza, W. Hamizan, et al.
Publicado: (2013)

Fluticasone furoate/fluticasone propionate – different drugs with different properties
por: Biggadike, Keith
Publicado: (2011)

Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD – mixed treatment comparisons of clinical efficacy
por: Stynes, Gillian, et al.
Publicado: (2015)

Fluticasone furoate/vilanterol 92/22 µg once a day: a 12-month study on outcomes in mild to moderate asthma
por: Dal Negro, Roberto W., et al.
Publicado: (2018)

Seasonal allergic rhinitis: fluticasone propionate and fluticasone furoate therapy evaluated
por: Kariyawasam, Harsha H, et al.
Publicado: (2010)

Effect of once-daily fluticasone furoate/vilanterol versus vilanterol alone on bone mineral density in patients with COPD: a randomized, controlled trial
por: Maltais, Francois, et al.
Publicado: (2020)

24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study
por: Lipson, David A., et al.
Publicado: (2020)

Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects
por: Malerba, Mario, et al.
Publicado: (2018)

Safety of Once-Daily Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol in Japanese Patients with Asthma: A Long-Term (52-Week) Phase III Open-Label Study
por: Hozawa, Soichiro, et al.
Publicado: (2021)

Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials
por: Gross, Annette S., et al.
Publicado: (2015)

Fluticasone furoate nasal spray in the treatment of allergic rhinitis
por: Giavina-Bianchi, Pedro, et al.
Publicado: (2008)

Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19
por: Boulware, David R., et al.
Publicado: (2023)

Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma
por: Bernstein, David I, et al.
Publicado: (2011)

A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD
por: Crim, Courtney, et al.
Publicado: (2020)

Suppression of Cytokine Release by Fluticasone Furoate vs. Mometasone Furoate in Human Nasal Tissue Ex-Vivo
por: Zhang, Nan, et al.
Publicado: (2014)

A patient preference study that evaluated fluticasone furoate and mometasone furoate nasal sprays for allergic rhinitis
por: Yanez, Anahi, et al.
Publicado: (2016)

Mometasone furoate and fluticasone furoate are equally effective in restoring nasal epithelial barrier dysfunction in allergic rhinitis
por: Doulaptsi, Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ot0ak60ri6a6h1pgg9t1ao6ous